Literature DB >> 16430465

Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab.

B P Padate1, J Keidan.   

Abstract

A 75-year-old man, with a long history of recurrent lymphoplasmacytoid lymphoma, presented with diffuse large-cell lymphoma affecting adrenal glands and causing severe hypoadrenalism. The lymphoma responded to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy. Seven months postcompletion of chemotherapy, he developed signs of gastroenteritis and septicaemia. He deteriorated 24 h postadmission with a significant fall in Glasgow Coma Scale Score. Polymerase chain reaction testing of cerebrospinal fluid suggested enteroviral encephalitis. He responded symptomatically to intravenous immunoglobulins. His immunoglobulin levels were monitored weekly and supplemented to maintain immunoglobulin G level at 10 g/l, but in spite of this, his neurological condition deteriorated and he died after 14 weeks. Rituximab can cause prolonged B-cell deficiency. We speculate that profound immunosuppression induced by rituximab, together with previous chemotherapy, predisposed this patient to fatal enteroviral meningoencephalitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430465     DOI: 10.1111/j.1365-2257.2006.00751.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  8 in total

1.  Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Authors:  László Maródi; Jean-Laurent Casanova
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

3.  Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab.

Authors:  Najma Shaheen; Francis Mussai
Journal:  J Pediatr Hematol Oncol       Date:  2019-01       Impact factor: 1.289

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

5.  Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis.

Authors:  Ken-Hong Lim; Tzeun-Yuh Chiou; Cheng-Jui Lin; Ruey-Kuen Hsieh
Journal:  Med Oncol       Date:  2007-08-09       Impact factor: 3.064

Review 6.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.

Authors:  Simone Lanini; Aoife C Molloy; Paul E Fine; Archibald G Prentice; Giuseppe Ippolito; Christopher C Kibbler
Journal:  BMC Med       Date:  2011-04-12       Impact factor: 8.775

7.  Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: A case report and brief literature review.

Authors:  Roberto Tellez; Allison M Lastinger; Jeffery P Hogg
Journal:  IDCases       Date:  2019-05-09

Review 8.  Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review.

Authors:  Judith N Wagner; Annette Leibetseder; Anna Troescher; Juergen Panholzer; Tim J von Oertzen
Journal:  J Neurol       Date:  2021-03-06       Impact factor: 6.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.